| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS44015550 | HTLV-1 | ENSG00000203747.13 | protein_coding | FCGR3A | No | No | 2214 | P08637 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | FCGR3A |
|---|---|
| DrugBank ID | DB06607 |
| Drug Name | Catumaxomab |
| Target ID | BE0002097 |
| UniProt ID | P08637 |
| Regulation Type | agonist |
| PubMed IDs | 20347527 |
| Citations | Seimetz D, Lindhofer H, Bokemeyer C: Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy. Cancer Treat Rev. 2010 Oct;36(6):458-67. doi: 10.1016/j.ctrv.2010.03.001. Epub 2010 Mar 27. |
| Groups | Approved; Investigational; Withdrawn |
| Direct Classification | Peptides |
| SMILES | |
| Pathways | |
| PharmGKB | |
| ChEMBL |
